<DOC>
	<DOCNO>NCT01098240</DOCNO>
	<brief_summary>The primary objective study : 1 ) Evaluate efficacy CP 601,927 compare placebo augmentation antidepressant therapy ( ADT ) patient Major Depressive Disorder ( MDD ) use Montgomery Asberg Depression Rating Scale ( MADRS ) . 2 ) Evaluate safety tolerability CP 601,927 patient MDD ADT .</brief_summary>
	<brief_title>A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression</brief_title>
	<detailed_description>The study stop interim analysis August 2011 , stop criterion futility meet . There statistically significant change primary efficacy scale favor drug . There small chance additional data could change study overall outcome . There concern regard subject safety .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Medically healthy male female age 1865 ( inclusive ) . Patients must primary current diagnosis MDD without psychotic feature . Patients must receive ongoing antidepressant therapy time screen . Duration current episode MDD must least 8 week prior enrollment without adequate response treatment . Patients psychiatric disorder . Patients use tobacco product . Alcohol substance abuse dependence . Treatment monoamine oxidase inhibitor within 10 week enrollment . Pregnancy breastfeed . Clinically significant abnormality laboratory test , electrocardiogram , physical neurologic examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Antidepressant Augmentation</keyword>
</DOC>